Clinical Trial Update: Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma [Phase 1]

View source ↗

Summary

This entry reports the completion of a Phase 1 study evaluating Oral OSI-027 in patients with advanced solid tumors or lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumor

Drugs mentioned

• OSI-027

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Any Solid Tumor or Lymphoma | Phase 1 | Status: COMPLETED